StackItSmart

Compound reference

Pregnenolone

Ancillary compounds1 cited findingClinical review: not reviewed

Clinical & experimental findings

Human randomized studyAbstract inspected

In an eight-week adjunctive trial in patients with schizophrenia (56 pregnenolone, 55 placebo, after a placebo lead-in), pregnenolone improved the UPSA-B functional-capacity composite score versus placebo (P=.03) but not the MATRICS composite cognitive score. The functional-capacity improvement correlated with serum pregnenolone change only among the 17 female participants (P<.042), not among males. General claims that it improves cognition or restores hormones exceed these results.[1]

  • Disease-specific adjunctive study with mixed endpoints and a small female-only subgroup correlation; no hormone-restoration or post-anabolic-steroid recovery outcome was tested.
  • Abstract-checked; no qualified clinical review.
Inspection history

Clinical review: not reviewed by a qualified clinician.

· Independent source inspection; applicability narrowed and inherited assertions excluded where unsupported. No qualified clinical review.

· Reopened the PubMed structured abstract via E-utilities and added exact group sizes, P values and the female-only correlation. No PMC full text available. Independent editorial review pending; no qualified clinical review.

What remains unresolved

Editorial assessment

These notes describe the scope of this review. Linked PMIDs are audit identifiers; an identifier alone does not verify a claim.

Narrowly supported passages published with study/product limits; remaining inherited assertions withheld from established-fact displays.

  • Not a comprehensive systematic review. Original monograph topics beyond the individual published claims—including monitoring schedules, contraindication lists, recovery assurances and detailed mechanisms—remain unverified.
  • No qualified clinician has reviewed these claims. Long-term outcomes and all marketed formulations have not been fully assessed.

This reference does not supply a dosing plan, monitoring timetable or recovery regimen. Discuss personal symptoms, medicines and laboratory results with a qualified clinician.

Explore the interaction evidence for this compound →

References

  1. Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia.

    Marx CE, Lee J, Subramaniam M, Rapisarda A, Bautista DC, Chan E, Kilts JD, Naylor JC, Bincy L, Verma S, Sim K, Hariram J, Jacob R, Keefe RS, Chong SA. Psychopharmacology (Berl). 2014 Sep;231(17):3647-3662. doi: 10.1007/s00213-014-3673-4. 2014-09. PMID:25030803 · DOI:10.1007/s00213-014-3673-4 Abstract only.

    Inspected location: PubMed abstract (full structured text): primary endpoints (MCCB cognitive composite, UPSA-B functional-capacity composite, SANS negative-symptom total) and the female-only correlation with serum pregnenolone change

    Study context and inspection record

Source inspection and clinical review are separate. An abstract check is not a full-text review. The records above identify what was actually inspected and do not certify the complete literature.

Recorded verification attempts
  • Fresh PubMed EUtils retrieval for inherited lead PMID 25030803; identity, abstract and linked corrections checked where an abstract existed.
  • https://pubmed.ncbi.nlm.nih.gov/25030803/ — abstract; PubMed abstract: Results: functional-capacity endpoint versus composite cognitive endpoint; Methods: adjunctive schizophrenia trial

View this compound in the research library →

Related records in this class

Grouped under Ancillary compounds for navigation only. Shared class membership does not make findings, formulations or evidence interchangeable between records.

StackItSmart

Age confirmation

This reference discusses steroids, SARMs and other compounds. It is educational, not medical advice, and does not recommend using or combining them.

Your confirmation is saved in this browser when storage is available.